androgen deprivation therapy

February 23, 2021February 23, 2021

Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

News

Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk disease will benefit from adding androgen deprivation therapy (ADT) ... Read more

February 16, 2021February 16, 2021

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

News

When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — without compromising their quality of ... Read more

January 14, 2021January 14, 2021

Nubeqa Prescribing Information Updated With New Survival Data

News

The prescribing information for Nubeqa (darolutamide) — used to treat men with prostate cancer that has not spread to other parts of the body — will be updated to include ... Read more

January 5, 2021January 5, 2021

Long-term ADT Found to Raise Risk of Cardiovascular Death

News

Long-term exposure to androgen deprivation therapy (ADT), a common treatment for prostate cancer, is associated with worse cardiorespiratory fitness and a higher risk of cardiovascular death, a new study reports. ... Read more

October 22, 2020October 22, 2020

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

News

Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase ... Read more

September 29, 2020September 29, 2020

Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows

News

Nearly all men with non-metastatic castration-resistant prostate cancer (nmCRPC) received the full planned dose of Nubeqa (darolutamide) tablets while participating in the ARAMIS Phase 3 trial, and few required dose ... Read more

June 25, 2020June 25, 2020

Relugolix Granted FDA Priority Review as New Treatment Type

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) Myovant Sciences submitted earlier this year requesting the approval of relugolix for the ... Read more

June 2, 2020June 2, 2020

ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests

News

Androgen deprivation therapy (ADT), a form of hormone therapy commonly used to treat prostate cancer, appears to confer protection against the virus that causes COVID-19, lowering the rate of infections ... Read more

April 24, 2020April 24, 2020

FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

News

Myovant Sciences has filed an application with the U.S. Food and Drug Administration (FDA) seeking approval of relugolix to treat men with advanced prostate cancer. The new drug application (NDA) proposes a single ... Read more

January 29, 2020January 30, 2020

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

News

The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition known ... Read more